Science to practice: Can theranostic fullerenes be used to treat brain tumors?

Research output: Contribution to journalShort survey

Abstract

In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd3N@C80) labeled with lutetium 177(177Lu) and tetraazacyclododecane tetraacetic acid (DOTA)(177Lu-DOTA-f- Gd3N@C80) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalRadiology
Volume261
Issue number1
DOIs
StatePublished - Oct 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this